Please login to the form below

Not currently logged in
Email:
Password:

Letermovir

This page shows the latest Letermovir news and features for those working in and with pharma, biotech and healthcare.

EC grants MSD’s Prevymis orphan product designation

EC grants MSD’s Prevymis orphan product designation

The status for Prevymis ’ (letermovir) covers the prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). ... to help ensure that appropriate

Latest news

  • CHMP backs MSD’s CMV infection treatment CHMP backs MSD’s CMV infection treatment

    Merck Sharp &Dohme (MSD) is closing on European approval for its infection treatment Prevymis (letermovir) after it received backing from the Committee for Medicinal Products for Human Use’s (CHMP) last ... The US Food and Drug Administration approved

  • Merck says drug for CMV in transplant patients hits targets Merck says drug for CMV in transplant patients hits targets

    Merck says drug for CMV in transplant patients hits targets. Letermovir on course for fast-track 2017 filing and head start in prospective $350m market. ... Letermovir has been granted orphan drug status in the EU and the US, and has also been earmarked

  • Merck & Co pays €110m upfront for AiCuris' CMV portfolio Merck & Co pays €110m upfront for AiCuris' CMV portfolio

    Merck &Co pays 110m upfront for AiCuris' CMV portfolio. Lead candidate is orphan drug letermovir for transplant patients. ... Letermovir has been granted orphan drug status in the EU and the US, and has also been earmarked for fast-track review by the FDA

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    Letermovir has orphan drug status in the EU and the US, where it has also been granted fast track designation. ... 587. AiCuris / Merck &Co. Licence. Letermovir (phase IIb) and antiviral portfolio for CMV.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics